
Product Data Sheet

Product Name: SSR128129E free acid

Cat. No.: GC37679

Chemical Properties

Cas. No. 848463-13-8

SMILES COC1=C2N(C(C(C3=CC=C(N)C(C(O)=O)=C3)=O)=C1C)C=CC=C2Formula $C_{18}H_{16}N_2O_4$ M.Wt 324.33

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

SSR 128129E is a potent inhibitor of the FGF receptor (FGFR; $IC_{50} = 1.9$ nM).¹ It reduces FGF2-induced endothelial cell proliferation and migration (IC_{50} s = 31 and 15.2 nM, respectively), as well as lamellipodia formation *in vitro*. SSR 128129E also reduces proliferation of PAE cells expressing FGFR1, mPanc02 cells expressing FGFR2, hB9 myeloma cells expressing FGFR3, and HUVECs expressing FGFR4 when used at a concentration of 100 nM. *In vivo*, SSR 128129E (30 mg/kg per day) reduces limb swelling, redness, and deformity and improves performance in an exercise endurance test in a mouse model of arthritis. It reduces tumor growth and metastasis and enhances antitumor activity of the VEGF receptor (VEGFR) antibody α VEGFR2 in a Panc02 mouse orthotopic tumor model. SSR 128129E (50 mg/kg per day) reduces atherosclerotic lesion size in the aortic sinus of apoE^{-/-} mice.² It also reduces intimal hyperplasia following jugular vein-to-artery bypass grafting surgery in rats.³

1. Bono, F., De Smet, F., Herbert, C.A., et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties *Cancer Cell* 23(4)477-488(2013)
 2. Dol-Gleizes, F., Delesque-Touchard, N., Marés, A.M., et al. A

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice PLoS

One 8(11)e80027(2013) 3.Huang, Q.-X., Liang, L.-D., Lan, Z.-C., et al. Effects of

ssr128,129e on intimal hyperplasia in autogenous vein grafts of rats Shiyong Yixue

Zazhi 31(2)188-190(2015)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA